Adir Et Compagnie

Science Union Et Cie

Adir Et Cie

Adir

Science Union Et Cie, Societe Francaise De Recherche Medicale

Adir, S.a.r.l.

Adir Et Lie

Georges Remond

Michel Vincent

Michel Laubie

Guillaume De Nanteuil

Bernard Portevin

Jean Lepagnol

Yolande Herve

Bernard Marchand

Jean Baliarda

Tony Verbeuren

Ghanem Atassi

Jacqueline Bonnet

Jean-Claude Poignant

Jacques Bure

Claude Cudennec

Alain Pierre

Xavier B Pascaud

Emmanuel Canet

Gordon Tucker

Massimo Sabatini

Joseph Paladino

Jean-Albert Boutin

Jacques Duhault

Michel Lonchampt

Graham Birrell

Catherine Biton

Bernard Protevin

Veronique Heidet

Michelle Boullanger

Compound of formula (I): ##STR1## in which: m represents an integer from 1 to 4 inclusive, and n and p an integer from 0 to 4 inclusive,

Metalloproteinase inhibitors

Compound of formula (I): ##STR1## in which: m, n, which are identical or different, represent 0, 1 or 2,

Metalloprotease inhibitors

The invention relates to the compounds of formula (I): ##STR1## in which: R.sub.1 represents alkyl, phenyl, naphthyl, pyridyl or thienyl group, each phenyl, naphthyl, pyridyl or thienyl optionally being substituted,

Piperidine compounds

Compound of formula (I): ##STR1## in which: R.sub.1 represents a hydroxyl, alkoxy or amino (unsubstituted or substituted) group,

Preparation of phosphoramidon

New phosphonic acid compounds

Compounds of formula (I): ##STR1## wherein: R.sub.1 represents an unsubstituted or substituted alkyl,

Peptides derived from trifluoromethylketones

The invention relates to the compounds of formula (I): ##STR1## in which: A represents, with the carbon and nitrogen atoms to which it is attached, a heterocycle,

Bicyclic nitrogen compounds

Phosphonic acid compounds

The invention relates to the compounds of formula (I): ##STR1## in which: A represents, with the nitrogen and carbon atoms to which it is bound, a heterocycle,

Nitrogen-containing bicyclic compounds and pharmaceutical compositions

The invention relates to a compound of formula (I): ##STR1## which can be used as N-myristoyltransferase inhibitors, in which R.sub.1 represents hydrogen, substituted or unsubstituted (C.sub.1 -C.sub.6) alkyl, substituted or unsubstituted phenyl, (C.sub.3 -C.sub.7) cycloalkyl methyl, substituted or unsubstituted (imidazolyl-2-yl)methyl, substituted or unsubstituted (indol-3-yl)methyl or (1-azaindolizin-2-yl)methyl,

N-myristoyl transferase inhibitors

The invention relates to compounds of formula (I): ##STR1## in which: A represents, with the carbon and nitrogen atoms to which it is linked, cyclic amide as defined in the description,

Peptide compounds containing a cyclic amide structure

The invention relates to the use of N-myristoyl-(S)-phenylalanine in the treatment of diseases involving myristoylation such as cancer or AIDS. Medicinal products including N-myristoyl-(S)-phenylalanine which are effective for such purpose.

Use of N-myristoyl-(S)-phenylalanine for the treatment of diseases

The invention relates to the compounds of formula (I): ##STR1## in which: R.sub.1 represents a linear or branched, lower or higher alkoxy group or a substituted or unsubstituted amino group,

Substituted amino acid compounds

The invention relates to the compounds of general formula (I): ##STR1## in which: A represents, with the carbon and nitrogen atoms to which it is linked, a cycloamide group,

New heterocyclic tripeptide compounds

Growing community of inventors

Versailles, France

Georges Remond